Skip to main content
BeyondSpring Inc. logo

BeyondSpring Inc. — Investor Relations & Filings

Ticker · BYSI ISIN · KYG108301006 US Manufacturing
Filings indexed 233 across all filing types
Latest filing 2023-02-28 Foreign Filer Report
Country US United States of America
Listing US BYSI

About BeyondSpring Inc.

https://www.beyondspringpharma.com/en/

BeyondSpring Inc. is a clinical-stage biopharmaceutical company that develops innovative immuno-oncology cancer therapies. The company's primary focus is on addressing unmet medical needs and improving clinical outcomes for cancer patients. Its pipeline includes a lead asset, Plinabulin, which is a first-in-class small molecule agent. Additionally, the company operates a Targeted Protein Degradation (TPD) platform to advance other potential treatments. BeyondSpring is committed to developing novel cancer therapies to enhance the standard of care in oncology.

Recent filings

Filing Released Lang Actions
FORM 6-K
Foreign Filer Report
2023-02-28 English
6-K
Foreign Filer Report
2023-02-24 English
SC 13G/A
Major Shareholding Notification
2023-02-14 English
6-K
Foreign Filer Report
2023-01-09 English
6-K
Foreign Filer Report
2022-12-30 English
6-K
Foreign Filer Report
2022-11-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.